Keyphrases
COVID-19
100%
Histoplasmosis
52%
Invasive Fungal Infection
35%
Mycoses
28%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
23%
Itraconazole
23%
Cryptococcosis
23%
SARS-CoV-2 Infection
22%
Candida Bloodstream Infection
21%
Modern History
21%
Clinical Prediction Model
21%
Cryptococcal Infection
21%
People Living with HIV (PLHIV)
19%
Azoles
18%
Group Research
17%
Research Consortium
17%
Group Education
17%
Odds Ratio
16%
Disseminated Infection
16%
Step-down
15%
Patients with COVID-19
15%
Hospitalized Patients
15%
Randomized Clinical Trial
14%
Safety Profile
14%
Confidence Interval
14%
Adjunctive Therapy
12%
B Cells
12%
Placebo
12%
Retrospective Cohort
12%
Immune Status
12%
Amphotericin B
12%
United States
11%
Antifungal Therapy
11%
Disease Severity
11%
Propensity Score Analysis
10%
Intubated Patients
10%
Attributable Mortality
10%
Asthma
10%
T-2307
10%
Rezafungin
10%
Toxic Interaction
10%
Olorofim
10%
Aureobasidin A
10%
Neurapheresis
10%
Fosmanogepix
10%
Antimicrobial-resistant Organisms
10%
Glucan Synthesis
10%
Lactobacillus Rhamnosus GG
10%
Fungal Pretreatment
10%
AR-12
10%
Medicine and Dentistry
COVID-19
83%
Infection
71%
Severe Acute Respiratory Syndrome Coronavirus 2
57%
Disease
34%
Histoplasmosis
31%
Cryptococcosis
23%
Systemic Mycosis
22%
Mycosis
21%
Human Immunodeficiency Virus
19%
Randomized Clinical Trial
14%
Disseminated Disease
14%
Adjuvant Therapy
12%
Antifungal Therapy
11%
Disease Severity
11%
Geographic Distribution
10%
Adverse Outcome
10%
Complement Activation
10%
Asthma
10%
Coronavirinae
10%
Cenicriviroc
10%
Echinocandins
10%
Rezafungin
10%
Ibrexafungerp
10%
Aureobasidin A
10%
Olorofim
10%
Nikkomycin Z
10%
Antigen Antibody Reaction
10%
Clostridium Difficile Infection
10%
Cohort Analysis
10%
Hydroxychloroquine
10%
Blastomycosis
10%
Coccidioidomycosis
10%
Lateral Flow Assay
10%
Chloroquine
10%
Microbiome
10%
Acute Respiratory Distress Syndrome
10%
Meta-Analysis
10%
Dimorphic Fungal Infection
10%
Drug Resistance
10%
Enzyme Linked Immunosorbent Assay
10%
Infliximab
10%
Mitochondrial DNA
10%
Placebo
10%
Cell Wall
10%
Abatacept
10%
Pyrrole Derivative
10%
Mineralocorticoid
10%
Paralysis
10%
Immunity
10%
Bloodstream Infection
10%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
59%
Infection
52%
SARS Coronavirus
34%
Systemic Mycosis
33%
Coronavirinae
33%
Histoplasmosis
31%
Mycosis
31%
Candida
24%
Itraconazole
23%
Bloodstream Infection
21%
Cryptococcosis
21%
Antifungal Agent
19%
Randomized Clinical Trial
14%
Placebo
14%
Antiinfective Agent
14%
Pyrrole Derivative
12%
Amphotericin B
12%
Comorbidity
11%
Chloroquine
10%
HIV
10%
Hydroxychloroquine
10%
Adverse Outcome
10%
Lactobacillus rhamnosus
10%
Olorofim
10%
Aureobasidin A
10%
Nikkomycin Z
10%
Clostridium Difficile Infection
10%
Echinocandins
10%
Rezafungin
10%
Mitochondrial DNA
10%
Candidiasis
10%
Cenicriviroc
10%
Mineralocorticoid
10%
Abatacept
10%
Infliximab
10%
Asthma
10%
Adult Respiratory Distress Syndrome
10%
Fluconazole
10%
Paralysis
10%
Bioavailability
10%
Drug Resistance
10%
Ibrexafungerp
10%
Route of Administration
10%
Randomized Controlled Trial
10%
Voriconazole
10%
Antifungal Therapy
10%
Invasive Candidiasis
10%
Addison Disease
10%
Replacement Therapy
8%
Liquorice
7%
